Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.
Study Type
OBSERVATIONAL
Enrollment
224
CHRU de Nancy
Nancy, Grand Est, France
Proportion of abortive hemangioma among infantile hemangioma
Proportion of abortive hemangioma among infantile hemangioma
Time frame: baseline
To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex
Compare sex predominance between infantile hemangioma and abortive hemangioma
Time frame: baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity
Compare prematurity rates between infantile hemangiomas and abortive hemangiomas
Time frame: baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight
Compare birthweight between infantile hemangiomas and abortive hemangiomas
Time frame: baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization
Compare localization between infantile hemangiomas and abortive hemangiomas
Time frame: baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment
le hemangiomas and abortive hemangiomaCompare treatment between infanti
Time frame: baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications
Compare complications between infantile hemangiomas and abortive hemangioma
Time frame: baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size
Compare size (focal, extended or segmental) between infantile hemangiomas and abortive hemangioma
Time frame: baseline
To study the evolution of abortive hemangioma : erythematous macule
Evaluation of the fading of erythematous macule between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
To study the evolution of abortive hemangioma : papules of proliferation
Evaluation of the regression of the papules of proliferation between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
To study the evolution of abortive hemangioma : telangiectasias
Evaluation of the fading of telangiectasias between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
To study the evolution of abortive hemangioma : halo of vasoconstriction
Evaluation of the fading of the vasoconstricted halo between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
To study the evolution of abortive hemangioma : areas of vasoconstriction
Evaluation of the fading of vasoconstricted areas between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
To study the evolution of abortive hemangioma : dilated veins
Evaluation of the fading of dilated veins between the stage of maximal proliferation and the last follow-up
Time frame: through study completion, an average of 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.